关于成都先导药物开发股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 Deloitte. 会计师事务所(特殊普通合伙) 关于成都先导药物开发股份有限公司 控股股东、实际控制人及其他关联方资金占用情况的专项说明 德师报(函)字(24)第 Q00905 号 成都先导药物开发股份有限公司董事会: 我们接受委托,依据中国注册会计师审计准则审计了成都先导药物开发股份有限公司(以下简称 "贵公司")2023年12月31日合并及母公司资产负债表,2023年度合并及母公司利润表、合并及母 公司现金流量表、合并及母公司股东权益变动表以及相关财务报表附注(以下合称"财务报表"),并 于 2024年 4 月 23 日签发了德师报(审)字(24)第 P04370 号无保留意见的审计报告。 2、 附表 委托单位：成都先导药物开发股份有限公司 审计单位：德勤华永会计师事务所(特殊普通合伙) 联系电话：028-6223 7016 成都先导药物开发股份有限公司 控股股东、实际控制人及其他关联方 资金占用情况的专项说明 2023 年 12 月 31 日止年度 根据中国证券监督管理委员会联合 ...

Financial Performance - The proposed cash dividend distribution for 2023 is CNY 0.5 per share, totaling CNY 19,972,065, which accounts for 49.05% of the net profit attributable to shareholders[6]. - The company reported a total revenue of $X billion for the fiscal year 2023, representing a Y% increase compared to the previous year[12]. - The company achieved operating revenue of CNY 371.32 million in 2023, representing a year-on-year growth of 12.64%[23]. - The net profit attributable to shareholders reached CNY 40.72 million, an increase of 61.16% compared to the previous year[23]. - The net cash flow from operating activities was CNY 125.21 million, showing a significant increase of 137.42% year-on-year[23]. - The total revenue for 2023 reached ¥371,066,386.37, representing a 12.56% increase from ¥329,650,037.29 in 2022[161]. - The gross margin for the main business improved to 49.28%, an increase of 1.61 percentage points from 47.67% in 2022[164]. - The revenue from new drug research and development services reached ¥369,179,593.92, representing an 18.08% increase year-over-year, with a gross margin of 49.03%[169]. R&D and Innovation - The company has outlined various risks it may face in its operations, which are detailed in the report[5]. - The R&D budget has been increased by J%, focusing on the development of K new technologies and products[12]. - The company has focused on optimizing its internal drug pipeline while maintaining investments in its core technology platforms[27]. - The company has synthesized over 1.2 trillion structurally diverse DNA-encoded compounds, demonstrating its capability in screening lead compounds against known and emerging biological targets[52]. - The company is actively integrating AI into drug discovery processes, leveraging extensive screening data to enhance compound activity predictions and optimize drug development[49]. - The company has developed a DNA-encoded compound library (DEL) with over 12 trillion small molecules, making it the largest known physical small molecule library globally[129]. - The company has established a nucleic acid drug research platform, capable of designing and synthesizing high-activity and high-selectivity nucleic acid sequences[90]. - The company has published over 30 original scientific papers in the DEL field, enhancing innovation and development in DEL technology[130]. Market and Strategic Positioning - The company is expanding its market presence in regions E and F, aiming for a market share increase of G% by the end of 2024[12]. - The global pharmaceutical market was valued at approximately $1.48 trillion in 2022, projected to reach $1.8 trillion by 2025, indicating strong growth potential[62]. - The company aims to enhance its R&D capabilities and increase investment in innovative drug development, driven by favorable policy changes in China[199]. - The company plans to become a global leader in innovative biopharmaceuticals, addressing unmet clinical needs[200]. - The company has a strategic focus on drug discovery and development, aiming to establish itself as a "seed bank" for innovative drugs in China and globally[200]. Compliance and Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company has not experienced any instances where more than half of the board members could not guarantee the authenticity, accuracy, and completeness of the annual report[8]. - The company has confirmed that all board members attended the board meeting[6]. - The company has received a standard unqualified audit report from Deloitte Huayong[6]. Risks and Challenges - The company faces risks related to new drug development failures, particularly as it targets novel mechanisms and pathways, which inherently carry higher R&D failure risks compared to traditional drug types[146]. - The company faces risks related to the loss of core technical talent and potential leakage of core technologies, which could adversely affect its competitive position and profitability[148]. - The company is exposed to foreign exchange risks due to a significant portion of its revenue being denominated in USD and GBP[151]. - The company has a high customer concentration, which poses risks if major clients experience operational difficulties or if market development does not meet expectations[150]. Acquisitions and Collaborations - The acquisition of Vernalis (R&D) has positioned the company as a leader in FBDD/SBDD, with over 20 years of experience in drug discovery technology[74]. - The company established deep collaborations with several global biopharmaceutical companies and research institutions to advance R&D project commercialization[38]. - Chengdu XianDao has established partnerships with multiple international pharmaceutical companies, biotechnology firms, and research institutions, aiming to become a global innovation drug "seed bank" and "new engine" for drug creation[53]. Operational Efficiency - The company has implemented a new strategy to optimize operational efficiency, targeting a reduction in costs by L% over the next year[13]. - The company has a dedicated team of nearly 80 professionals in various fields, enhancing its capabilities in drug discovery and development[89]. - The company has established a comprehensive drug optimization system covering various technical aspects, from recombinant protein expression to pharmacokinetics[95].

成都高新区交子大道 233 号 中海国际中心 C 座 28 层 邮编：610041 电话：（86-28）6739-8000 传真：（86-28）6739-8001 junhecd@junhe.com 北京君合（成都）律师事务所 关于 成都先导药物开发股份有限公司 2023 年限制性股票激励计划部分限制性股票作废事项 之 法律意见书 二零二四年四月 关于成都先导药物开发股份有限公司 2023 年限制性股票激励计划部分限制性股票作废事项 之法律意见书 致：成都先导药物开发股份有限公司 北京君合（成都）律师事务所（以下简称"本所"）为在四川省司法厅注册 设立并依法执业的律师事务所。 本所受成都先导药物开发股份有限公司（以下简称"公司""上市公司"或 "成都先导"）的委托，担任成都先导 2023 年限制性股票激励计划（以下简称 "本次激励计划"）的专项法律顾问，依据《中华人民共和国公司法》（以下简 称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上市 公司股权激励管理办法》（以下简称《管理办法》）、《上海证券交易所科创板 股票上市规则》（以下简称《上市规则》）、《科创板上市公司自律监管指南第 4 号 ...

成都先导药物开发股份有限公司 董事会审计委员会 2023 年度履职报告 根据《上海证券交易所科创板股票上市规则》、《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》以及《公司章程》、《审计委员会工作细 则》等相关规定，成都先导药物开发股份有限公司（以下简称"公司"）董事会 审计委员会认真履行审计监督职责，积极开展审计委员会工作，现对 2023 年度 履职情况报告如下： 1、监督及评估外部审计机构工作 报告期内，董事会审计委员会对公司聘请的 2023 年度审计机构德勤华永会 计师事务所（特殊普通合伙）的审计工作进行了监督与评估，认为该机构在为本 公司年报审计过程中能够严格按照国家有关规定以及注册会计师职业规范的要 求开展审计工作，遵循独立性原则发表客观公正的审计意见，相关审计意见客观 公正，审计报告真实、准确、完整反映了公司的整体情况。 2、对公司内部审计工作指导情况 2023 年度，公司董事会审计委员会充分发挥专业委员会作用指导公司内部 审计工作，同时督促公司内部审计严格按照审计工作计划执行，对内部审计提出 了指导性建议，提高了内部审计的工作成效。 一、董事会审计委员会基本情况 公司第二届董 ...

成都先导药物开发股份有限公司 2024 年"提质增效重回报"行动方案 成都先导（688222.SH） 为促进公司高质量发展，践行"以投资者为本"的发展理念，维 护全体股东利益，成都先导药物开发股份有限公司（以下简称"公司" 或"成都先导"）积极响应上海证券交易所关于开展科创板上市公司 "提质增效重回报"专项行动的倡议，结合自身战略目标及实际情况、 宏观经济形势、行业发展趋势及市场需求态势制定 2024 年"提质增 效重回报"行动方案。 一、 成都先导发展现状 成都先导聚焦小分子及核酸新药的发现与优化，依托 DEL 技术 （包括 DEL 库的设计、合成和筛选及拓展应用）、基于分子片段和 三维结构信息的药物设计（FBDD/SBDD）技术、寡聚核酸新药研发 平台相关技术（STO）、靶向蛋白降解平台相关技术（TPD）四大核 心技术平台及公司其他关键新药研发能力（药物化学、计算科学/AI、 体外体内生物学评价、药物代谢学，分析化学，药学研究等），打造 新药发现与优化的国际领先的研发体系，通过新药研发服务、不同阶 段在研项目转让及远期的药物上市，为医药工业输出不同阶段的新分 子实体，以最终为全球未满足的临床需求提供创新药 ...

成都高新区交子大道 233 号 中海国际中心 C 座 28 层 邮编：610041 电话：（86-28）6739-8000 传真：（86-28）6739-8001 junhecd@junhe.com 北京君合（成都）律师事务所 关于 成都先导药物开发股份有限公司 2021 年限制性股票激励计划部分限制性股票作废事项 之 法律意见书 二零二四年四月 关于成都先导药物开发股份有限公司 2021 年限制性股票激励计划部分限制性股票作废事项 之法律意见书 致：成都先导药物开发股份有限公司 北京君合（成都）律师事务所（以下简称"本所"）为在四川省司法厅注册 设立并依法执业的律师事务所。 本所受成都先导药物开发股份有限公司（以下简称"公司""上市公司"或 "成都先导"）的委托，担任成都先导 2021 年限制性股票激励计划（以下简称 "本次激励计划"）的专项法律顾问，依据《中华人民共和国公司法》（以下简 称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上市 公司股权激励管理办法》（以下简称《管理办法》）、《上海证券交易所科创板 股票上市规则》（以下简称《上市规则》）、《科创板上市公司自律监管指南第 4 号 ...

中国国际金融股份有限公司 关于成都先导药物开发股份有限公司 2023 年度募集资金存放与使用情况的专项核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为 成都先导药物开发股份有限公司（以下简称"成都先导"或"公司"）首次公开 发行股票并在科创板上市及持续督导的保荐机构，根据《上市公司监管指引第2 号——上市公司募集资金管理和使用的监管要求》《证券发行上市保荐业务管理 办法》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》《上 海证券交易所科创板股票上市规则》《上海证券交易所上市公司自律监管指引第 11号——持续督导》等有关法律法规和规范性文件的要求，中金公司及其指定保 荐代表人对成都先导2023年度募集资金存放与使用情况进行了专项核查，核查情 况与意见如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可[2020]429 号文《关于同意成都先导药 物开发股份有限公司首次公开发行股票注册的批复》同意，公司于 2020 年 4 月 16 日在上海证券交易所以每股人民币 20.52 元的价格公开发行 40,680,000 股人 ...

使用部分暂时闲置募集资金进行现金管理的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为成 都先导药物开发股份有限公司（以下简称"成都先导"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》等法律、行政法规、部门规章及业务规则， 对成都先导拟使用部分暂时闲置募集资金进行现金管理的事项进行了认真、审 慎的核查，核查情况如下： 中国国际金融股份有限公司 关于成都先导药物开发股份有限公司 （三）投资额度及期限 一、本次募集资金基本情况 根据中国证券监督管理委员会于 2020 年 3 月 17 日出具的《关于同意成都先 导药物开发股份有限公司首次公开发行股票注册的批复》（证监许可[2020]429 号），公司获准向社会公开发行人民币普通股 40,680,000 股，每股发行价格为 人民币 20.52 元，募集资金总额为人民币 834,753,600.00 元；扣除发行费用人民 ...

Financial Performance - The company's operating revenue for Q1 2024 reached ¥107,382,466.51, representing a year-on-year increase of 54.35%[5] - The net profit attributable to shareholders was ¥13,940,028.65, a significant recovery from a loss of ¥9,393,600 in the same period last year[8] - The net cash flow from operating activities was ¥40,865,611.68, showing a substantial increase of 106.61% compared to the previous year[5] - The weighted average return on equity increased to 1.00%, up by 1.72 percentage points from the previous year[5] - The company reported a significant increase in revenue from its DEL platform, which grew by 49.33% year-on-year[8] - Revenue from the UK subsidiary's project milestone income increased by 78.83% due to favorable exchange rate changes[8] - The basic and diluted earnings per share for the period were both ¥0.03, recovering from a loss of ¥0.02 per share in the same period last year[8] - Operating profit for Q1 2024 was ¥14,495,500.79, compared to an operating loss of ¥11,549,642.89 in Q1 2023[21] - Net profit for Q1 2024 was ¥13,910,097.65, a significant recovery from a net loss of ¥9,294,847.57 in Q1 2023[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,738,571,859.29, reflecting a slight increase of 0.52% from the end of the previous year[6] - Total assets as of Q1 2024 amounted to ¥1,738,571,859.29, slightly up from ¥1,729,558,879.03 in the previous year[17] - Total liabilities decreased to ¥340,243,739.36 from ¥346,566,991.96, a reduction of 1.8%[17] - Shareholders' equity increased to ¥1,398,328,119.93 from ¥1,382,991,887.07, reflecting a growth of 1.1%[17] Research and Development - Research and development (R&D) expenses totaled ¥12,989,221.09, a decrease of 37.09% year-on-year, with R&D expenses accounting for 12.10% of operating revenue, down 17.58 percentage points[6] - Research and development expenses for Q1 2024 were ¥12,989,221.09, down from ¥20,648,543.13 in Q1 2023, indicating a decrease of 37.4%[21] Cash Flow - In Q1 2024, the cash inflow from operating activities totaled $119.23 million, an increase of 13.9% compared to $104.62 million in Q1 2023[25] - The net cash flow from operating activities reached $40.87 million, up 106.5% from $19.78 million in the same period last year[25] - Cash inflow from investment activities was $584.47 million, compared to $547.15 million in Q1 2023, marking a 6.8% increase[25] - The net cash flow from investment activities improved significantly to $56.43 million, compared to a negative $103.31 million in Q1 2023[25] - The cash and cash equivalents at the end of Q1 2024 were $467.11 million, up from $267.06 million at the end of Q1 2023, representing a 75% increase[26] - The total cash outflow from financing activities was $3.04 million, slightly higher than $2.90 million in Q1 2023[26] - The company received $580 million from investment recoveries, an increase from $542 million in the previous year[25] - The cash paid for the purchase of fixed assets and intangible assets was $16.27 million, down from $26.72 million in Q1 2023, indicating a 39% decrease[25] - The company reported a tax refund of $1.92 million in Q1 2024, down from $4.81 million in Q1 2023[25] - The impact of exchange rate changes on cash and cash equivalents was a positive $260,766.14 in Q1 2024, compared to a negative impact of $2.87 million in Q1 2023[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,016[10] - The largest shareholder, JIN LI, holds 81,876,948 shares, representing 20.43% of total shares[10] - The second largest shareholder, Lhasa Economic and Technological Development Zone Huabo Medical Devices Co., Ltd., holds 50,870,579 shares, representing 12.70%[10] Current Assets - Total current assets as of March 31, 2024, amount to RMB 1,190,767,811.78, an increase from RMB 1,181,276,653.89 as of December 31, 2023[15] - Cash and cash equivalents are reported at RMB 473,690,627.37, up from RMB 377,398,358.67[15] - Trading financial assets decreased to RMB 510,083,888.89 from RMB 580,096,583.33[15] - Accounts receivable decreased to RMB 74,631,841.84 from RMB 96,822,078.91[15] - Inventory increased to RMB 30,010,252.14 from RMB 28,177,254.27[15] - Long-term equity investments decreased to RMB 11,449,172.19 from RMB 12,375,393.30[15] Other Comprehensive Income - The company reported a decrease in other comprehensive income, with a net amount of -¥67,452.95 compared to -¥3,250,700.35 in Q1 2023[22]

成都先导药物开发股份有限公司 关于作废部分已授予尚未归属的 2021 年 限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688222 证券简称：成都先导 公告编号：2024-010 4、2021 年 12 月 16 日，公司 2021 年第一次临时股东大会审议并通过了《关 于公司 2021 年限制性股票激励计划（草案修订稿）及其摘要的议案》《关于公司 2021 年限制性股票激励计划实施考核管理办法的议案》《关于提请公司股东大会 授权董事会办理股权激励相关事宜的议案》。本激励计划获得 2021 年第一次临时 股东大会的批准，董事会被授权确定限制性股票授予日、在条件成就时向激励对 象授予限制性股票并办理授予限制性股票所必须的全部事宜。2021 年 12 月 17 日，公司披露了《关于公司 2021 年限制性股票激励计划内幕信息知情人及激励 对象买卖公司股票情况的自查报告》。 5、2021 年 12 月 16 日，公司召开第一届董事会第二十次会议和第一届监事 会第十三次会议，审议通过了《关于调整 2 ...